Speaker illustration

Doctor Michael Davies

Lexicon Pharmaceuticals, Inc., The Woodlands (United States of America)

Member of:

European Society of Cardiology
Heart Failure Association

Sotagliflozin is effective in reducing heart failure risk of events in patients with HFpEF

Event: Heart Failure 2024

Topic: Pharmacotherapy

Session: Tailoring heart failure therapies on patient profiles


Efficacy and safety of the dual SGLT1 and 2 inhibitor sotagliflozin in combination with a mineralocorticoid receptor antagonist in patients hospitalized for worsening heart failure

Event: Heart Failure 2023

Topic: Pharmacotherapy

Session: ePosters in chronic heart failure - pharmacotherapy 2


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb